Biogen pays $120 million to Remedy Pharmaceuticals for stroke treatment Cirara
The US biotech announces that it has licensed a late-stage stroke drug that could be the first treatment advancement in the therapy area since the 1990s. Biogen will pay Remedy Pharmaceuticals $120 million for Cirara, which is currently heading towards Phase III trials in ischaemic stroke. If Ciara makes it to the market, it could